Stockscreener 앱 받기
14.84
2.56%
-0.39
시간 외 거래:
14.86
0.02
+0.13%
전일 마감가:
$15.23
열려 있는:
$15.46
하루 거래량:
1.23M
Relative Volume:
0.69
시가총액:
$1.72B
수익:
$674.41M
순이익/손실:
$-173.05M
주가수익비율:
-9.6722
EPS:
-1.5343
순현금흐름:
$-48.07M
1주 성능:
-15.92%
1개월 성능:
-2.05%
6개월 성능:
+19.68%
1년 성능:
+28.26%
1일 변동 폭
$14.83
$15.72
1주일 범위
$14.83
$18.15
52주 변동 폭
$9.82
$21.45
Novocure Ltd Stock (NVCR) Company Profile
명칭
Novocure Ltd
전화
44 (0)15 3475 6700
주소
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
14.84 | 1.97B | 674.41M | -173.05M | -48.07M | -1.5343 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-12-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-10-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-08-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 개시 | SVB Securities | Outperform |
| 2023-07-31 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2023-06-07 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2023-05-16 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 재확인 | H.C. Wainwright | Buy |
| 2022-11-29 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 개시 | H.C. Wainwright | Buy |
| 2022-02-08 | 개시 | Loop Capital | Buy |
| 2022-02-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2022-01-03 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-07-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-14 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-01-25 | 재확인 | Piper Sandler | Overweight |
| 2020-09-23 | 개시 | Northland Capital | Outperform |
| 2020-09-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | 다운그레이드 | Truist | Buy → Hold |
| 2020-06-01 | 재개 | Oppenheimer | Perform |
| 2020-05-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-04-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2020-03-05 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-29 | 업그레이드 | SunTrust | Hold → Buy |
| 2019-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-07-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2018-11-02 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 개시 | Evercore ISI | Outperform |
| 2018-04-18 | 재확인 | Mizuho | Buy |
| 2018-02-23 | 재확인 | Mizuho | Buy |
| 2017-05-24 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 재확인 | Wedbush | Outperform |
| 2016-01-19 | 개시 | Barclays | Underweight |
| 2015-12-02 | 개시 | Deutsche Bank | Hold |
모두보기
Novocure Ltd 주식(NVCR)의 최신 뉴스
Novocure Hits Record Revenue & Raises 2026 Outlook - Streetwise Reports
Novocure Ltd (NVCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Novocure Posts Record Q2 Revenue of US$183.6M - Streetwise Reports
NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
NovoCure Market Sentiment - Benzinga España
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade - Yahoo Finance Singapore
Novocure Ltd (NVCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NovoCure Ltd. (NVCRN) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
NovoCure (NVCR) Is Up 10.9% After Raising 2026 Revenue Outlook and Securing New CE Mark Approval – Has The Bull Case Changed? - simplywall.st
NovoCure Ltd. Revenue Breakdown – FWB:038 - TradingView
NovoCure Ltd. Revenue Breakdown – LSX:A140ML - TradingView
NovoCure Ltd. (NVCRN) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
NovoCure (NVCR) Lifts 2026 Guidance After Record Quarter While Fair Value Debate Builds - Yahoo Finance UK
TradingKey - TradingKey
Novocure Ltd (NVCR) Cash Flow - TradingKey
NovoCure (NVCR) Stock Faces Ongoing Losses As Q2 2026 EPS Narrows To $0.13 Loss - simplywall.st
Novocure Ltd (NVCR) Institutional Confidence - TradingKey
NVCR Maintained by Wedbush -- Price Target Raised to $20.00 - GuruFocus
H.C. Wainwright cuts NovoCure stock price target to $32 on valuation - Investing.com UK
Novocure Is Maintained at Neutral by Wedbush - Moomoo
NovoCure Posts Record Revenue and Raises Guidance, But NVCR Stock Tumbles Over 6% - finance.biggo.com
NVCR|Novocure Ltd|Price:17.010|Chg%:-0.640 - TradingKey
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding - Benzinga
Form 144 NovoCure Limited For: 24 July By Investing.com - Investing.com Nigeria
NovoCure (NVCR) Stock Soars 28% on Milestone Quarter and Strong Revenue Forecast - Blockonomi
NovoCure (NVCR) Stock Jumps 28% After Record Revenue and Raised Guidance - CoinCentral
NovoCure Q2 2026 slides: profitability in sight, guidance raised By Investing.com - Investing.com Nigeria
Novocure Ltd (NVCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Novocure Ltd earnings beat by $0.20, revenue topped estimates - Investing.com Nigeria
Novocure Cash, Cash Equivalents and Short-Term Investments Were $440.6M as of June 30 >NVCR - Moomoo
BR:N2VC34 Stock Latest News - TipRanks
NovoCure (NVCR) Breaks Out on Q2 2026 EarningsOptune Pax Driving Recovery - TradingKey
Novocure (NVCR) Hits New High on Optimistic Outlook, FDA Approval Hopes - Yahoo Finance
NovoCure Earnings Call Highlights Growth With Caution - TipRanks
NVCR Maintained by HC Wainwright & Co. -- Price Target Raised to $52 - GuruFocus
Earnings call transcript: NovoCure beats Q2 2026 forecasts, shares jump 16% - Investing.com Nigeria
NovoCure Ltd SEC Filing (Jul 23, 2026) - Stock Titan
NVCR Stock Surges 28% For Best Day In Over 1.5 Years — What’s Driving The Rally? - Yahoo Finance
NovoCure Ltd (NVCR) Q2 2026 Earnings Call Highlights: Record Rev - GuruFocus
NovoCure Ltd (NVCR) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... - Yahoo Finance
NovoCure's Q2 Net Loss Narrows, Revenue Rises; 2026 Revenue Guidance Raised - Moomoo
NovoCure Shares Surge 29% on Q2 Results, 2026 Forecast Raised - TechStock²
Crude Oil Rises Sharply; T-Mobile Shares Fall Following Q2 Results - Benzinga
Is Novocure Ltd (NVCR) Positioned for Growth After Q2 Earnings? - GuruFocus
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Top U.S. trending stocks: NovoCure leads with 23.4% surge - Investing.com
NovoCure surges on Q2 resultsGlobes - Globes - Israel Business News
Novocure stock hits 52-week high at 19.49 USD By Investing.com - Investing.com Nigeria
NovoCure Ltd Q2 2026 Financial Results: Revenue, R&D, and Key Risks Highlighted in Latest 10-Q Filing - Minichart
Novocure Reports Record Second-Quarter Revenue as Optune Expansion Drives Higher 2026 Outlook - Yahoo Finance
Earnings call transcript: NovoCure beats Q2 2026 forecasts, shares jump 16% By Investing.com - Investing.com South Africa
Novocure Ltd (NVCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Novocure Ltd 주식 (NVCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Leonard Frank X | Chief Executive Officer |
Jun 04 '26 |
Sale |
17.93 |
34,273 |
614,635 |
459,520 |
1.04%
11.95%
자본화:
|
볼륨(24시간):